75225-50-2 Usage
Uses
Used in Pharmaceutical Industry:
Lovastatin sodium salt is used as an intermediate for Brimonidine, a medication used to treat glaucoma and ocular hypertension. It plays a crucial role in the synthesis of this drug, contributing to its effectiveness in managing eye pressure.
Used in Metabolic Research:
As a metabolite of Lovastatin, Lovastatin sodium salt is used in metabolic research to study the effects of Lovastatin on cholesterol synthesis and its potential applications in treating hypercholesterolemia and other related conditions.
Used in Impurity Analysis:
Lovastatin sodium salt, specifically as Lovastatin EP Impurity B, is used in the analysis of impurities in the pharmaceutical manufacturing process. This helps ensure the quality and safety of the final drug product by identifying and controlling impurities that may affect its efficacy or cause adverse effects.
Check Digit Verification of cas no
The CAS Registry Mumber 75225-50-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,5,2,2 and 5 respectively; the second part has 2 digits, 5 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 75225-50:
(7*7)+(6*5)+(5*2)+(4*2)+(3*5)+(2*5)+(1*0)=122
122 % 10 = 2
So 75225-50-2 is a valid CAS Registry Number.
InChI:InChI=1/C24H38O6.Na/c1-5-15(3)24(29)30-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-18(25)12-19(26)13-22(27)28;/h6-7,10,14-16,18-21,23,25-26H,5,8-9,11-13H2,1-4H3,(H,27,28);/q;+1/p-1/t14-,15-,16-,18+,19+,20-,21-,23-;/m0./s1
75225-50-2Relevant articles and documents
PROCESSES FOR PREPARING AMINE SALTS OF SILDENAFIL-ANALOGUES AND USE THEREOF
-
Page/Page column 7, (2012/05/07)
A series of amine salts including a structure of formula (I) and formula (III) have provided. In formula I or formula (III), R1, Ra and RX are as defined in the specification. The amine complex salts disclosed in the present inventio
Parmaceutical
-
Page/Page column 4, (2008/06/13)
Use of one or more prenylation inhibitors, cholesterol biosynthesis inhibitors or HMG-CoA reductase inhibitors in the manufacture of a medicament for the treatment of hepatitis C virus (HCV) infection. The invention also encompasses a pharmaceutical composition for use in the treatment of HCV infection, the pharmaceutical composition comprising one or more agents capable of inhibiting prenylation, cholesterol biosynthesis or HMG-CoA reductase in the liver, wherein the one or more agents is optionally admixed with a pharmaceutically acceptable carrier, diluent or excipient.
HDL-boosting combination therapy complexes
-
Page/Page column 9, (2008/06/13)
A pharmaceutical composition including therapeutically effective amounts of at least one HMG-CoA reductase inibitor present as a dyhydroxyacid salt and at least one additional therapeutic agent.
